Atellica DCA AnalyserCompact. Portable. Scalable. Customisable.
Diabetes testing, evolved.
Building upon one of the industry’s most trusted technologies for diabetes testing, Atellica DCA Analyser puts fast, quality HbA1c and ACR results right at your fingertips. Experience the performance and precision you need to improve outcomes. Designed with the speed, standardisation, and personalisation you want to boost efficiencies and meet growing demand.
Benefits
Diabetes care – whether in a large hospital network or a busy clinical practice – consumes an ever-increasing share of healthcare time and resources. Atellica DCA Analyser adapts to your clinical and workflow needs to let your staff work the way they work best.
Offering accurate and actionable results in minutes, across the testing environment, the analyser makes diabetes testing fast and efficient for patients, providers, and organisations. Small footprint, light weight, and built-in handle enables easy movement for storage or bringing directly to patient.
Use patient-sample ID link to help mitigate the risk of misidentifying samples. Bring the handheld display directly to the patient, to scan and link the patient and cartridge information.
Atellica DCA Analyser was designed to provide confidence with every test. Simple operation and intuitive user interface (UI) decrease the likelihood of operator error, improves user experience, and reduces training complexity.
HbA1c results available in minutes can help ensure timely patient consultation and treatment paths. ACR results in only 7 minutes can help aid in the early diagnosis of kidney disease.
Building on 30+ years of innovation in HbA1c testing, our industry-leading immunoassay technology delivers reliable performance and excellent precision across the entire assay range, ensuring confidence test after test. Expand your diabetes management program to better serve your clinical staff and patients with Atellica DCA Analyser.
POCT has proven more effective in reducing HbA1c than other testing methods. Small sample size, rapid results, and the ability to process hemolysed samples mitigates pre-analytical errors and reduces patient discomfort from re-sticks.
Connect and operate up to three test modules with a single display to accommodate increasing testing volume.
POCT Informatics enables remote device monitoring, centralised compliance, operator management, and QC reporting. Seamlessly and securely transmit results to LIS/HIS/EHR systems with secure BLUETOOTH, Wireless or Wired connections.
Offering accurate and actionable results in minutes, across the testing environment, the analyser makes diabetes testing fast and efficient for patients, providers, and organisations. Small footprint, light weight, and built-in handle enables easy movement for storage or bringing directly to patient.
Technical Details
System Description
Point-of-care immunoassay analyser
Quantitative Tests
Hemoglobin A1c (whole blood)
4.0–14% (20–130 mmol/mol)ACR (urine)
Albumin: 5–300 mg/L
Creatinine: 15–500 mg/dL (1.3–44.2 mmol/L)
Albumin-to-creatinine ratio (ACR): 1–2000 mg/g (0.1–230.8 mg/mmol)Test Format
Self-contained immunoassay cartridges
Test Measurement
Automatic optical transmission
Test Results Units
Measured Parameters
HbA1c: %HbA1c (NGSP/DCCT) and mmol/mol (IFCC)
Albumin: mg/dL
Creatinine: mg/dL or mmol/LCalculated Parameters
ACR: mg/g or mg/mmolTest Method
HbA1c: monoclonal antibody agglutination reaction
Albumin: monoclonal antibody agglutination reaction
Creatinine: Benedict Behre chemical reaction
Time to Results
HbA1c: 5 minutes
ACR: 7 minutes
Sample Volume
HbA1c: 1 µL whole blood; capillary or venous (K2 EDTA, Li heparin, Na citrate)
ACR: 40 µL urine
Sample Prep
No pretreatment or pipetting required
Sample ID, Operator ID Entry
Optional, via touchscreen or built-in bar-code scanner
HbA1c Blood Sample Hold Time
4 minutes
Evidence
Confidence in results
Trusted performance
Atellica DCA Analyser is NGSP and IFCC Certified. You can feel confident with lab-quality* results at the point of care.
- Atellica DCA Analyser strongly correlated to results from the Tosoh G8 laboratory method.1
- No clinically significant interferences from common hemoglobin variants for HbA1c measurements.2
- Atellica DCA HbA1c test is not affected by hemolysed samples and can help reduce preanalytical errors.
On-demand Webinars
Breaking barriers: Leveraging novel therapies and lifestyle interventions for patients with diabetes and obesity
During this presentation Carlos Mendez, MD, F.A.C.P. reviews evidence-based strategies to support personalised multidisciplinary interventions for patients living with diabetes and obesity.
The connection between Covid-19 and diabetes: Where are we headed?
Demystifying HbA1c POC Testing and the Impacts of COVID-19 on Patients with Diabetes
Related Topics
The global impact of diabetes
Maps, facts, and figures about one of the largest global health issues of the 21st century
Point-of-Care Testing
Designed to provide rapid, convenient, and easy-to-use diagnostic testing
